Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Dermato-Onco2024 | The future role of neoadjuvant immunotherapies in advanced cSCC

Vasu Divi • 28 Oct 2024
Dermato-Onco2024
Skin Cancer Antibodies Atezolizumab Checkpoint Inhibitors

Vasu Divi, MD, Stanford Medicine, Stanford, CA, discusses the prospect of neoadjuvant checkpoint inhibitors becoming a part of the treatment paradigm for patients with advanced cutaneous squamous cell carcinoma (cSCC). Larger Phase III trials (NCT03833167, NCT03969004) are actively investigating the feasibility of neoadjuvant immunotherapies compared to surgical resection followed by adjuvant radiation therapy, which is the current standard of care provided to patients with advanced cSCC. This interview took place at The European Congress on Dermato-Oncology 2024 in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Vasu Divi

Identifying biomarkers in cutaneous SCC for enhanced patient screening
0:35
Identifying biomarkers in cutaneous SCC for enhanced patient screening
Vasu Divi • 28 Oct 2024
Developing personalized treatments for patients with cutaneous SCC
0:40
Developing personalized treatments for patients with cutaneous SCC
Vasu Divi • 28 Oct 2024
Neoadjuvant atezolizumab for advanced cutaneous squamous cell carcinoma
1:00
Neoadjuvant atezolizumab for advanced cutaneous squamous cell carcinoma
Vasu Divi • 28 Oct 2024

Related Videos

Cellular therapy advances and regulatory approvals in oncology in 2026
1:57
Cellular therapy advances and regulatory approvals in oncology in 2026
Paolo Ascierto • 23 Oct 2026
MELODY-1: MB097 and pembrolizumab in anti-PD-1-resistant melanoma
1:49
MELODY-1: MB097 and pembrolizumab in anti-PD-1-resistant melanoma
Paolo Ascierto • 23 Oct 2026
Comparing the current roles and toxicities of TILs and TCR cell therapy
2:53
Comparing the current roles and toxicities of TILs and TCR cell therapy
Marco Donia • 26 Oct 2026
iFOCUS: histotripsy boosting immune checkpoint inhibition in solid tumors
0:54
iFOCUS: histotripsy boosting immune checkpoint inhibition in solid tumors
Karijn Suijkerbuijk • 25 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals